KR960705544A - 단층라멜라 리포좀성 아라키돈산 대사물질 조성물을 사용한 치료방법(methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations) - Google Patents
단층라멜라 리포좀성 아라키돈산 대사물질 조성물을 사용한 치료방법(methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations)Info
- Publication number
- KR960705544A KR960705544A KR1019960702299A KR19960702299A KR960705544A KR 960705544 A KR960705544 A KR 960705544A KR 1019960702299 A KR1019960702299 A KR 1019960702299A KR 19960702299 A KR19960702299 A KR 19960702299A KR 960705544 A KR960705544 A KR 960705544A
- Authority
- KR
- South Korea
- Prior art keywords
- metabolite
- disease
- animal
- arachidonic acid
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
본 발명은 프로스타글란딘 E1과 같은 아라키돈산 대사물질을 동물에 투여하는 방법을 제공하는 것이다. 지질과 방출저해성 수용성 완충액으로 구성된 단층라멜라 리포좀과 연합된 대사물질은 일반적으로 사람인 동물에 투여될 수 있다. 본 발명은 세포활성과 흡착, 염증 또는 독혈증을 특징으로 하는 질환은 가진 동물의 치료에 사용될 수 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 혈소판응집에서 LUV-PGE1의 효과를 나타낸다, 제2도는 처리된/콘트롤 개에서 심장속도와 실험시간을 나타낸다, 제3도는 실험시간 대 좌측동맥 압력을 나타낸다, 제4도는 위험시에 지역%에서 경색크기를 나타낸다, 제5도는 심근조직에서 미엘로퍼옥시다제 방출을 나타낸다.
Claims (25)
- 동물에 아라키돈산 대사물질의 투여방법에 있어서, 아라키돈산 대사물질, 지질 그리고 방출 저해성 수용성 완충액으로 구성된 단층라멜라 리포좀과 제약학적 수용가능한 담체로 구성된 조성물을 동물에 투여하는 것으로 구성된 것을 특징으로 하는 방법.
- 제1항에 있어서, 동물은 사람인 것을 특징으로 하는 방법.
- 제1항에 있어서, 투여는 정맥투여인 것을 특징으로 하는 방법.
- 제1항에 있어서, 단층라멜라 리포좀은 직경이 약 100nm인 큰 단층라멜라 리포좀인 것을 특징으로 하는 방법.
- 제1항에 있어서, 아라키돈산 대사물질이 프로스타글란딘인 것을 특징으로 하는 방법.
- 제5항에 있어서, 프로스타글란딘이 프로스타글란딘 E1인 것을 특징으로 하는 방법.
- 제1항에 있어서, 지질은 포화된 아실사슬 저질은 것을 특징으로 하는 방법.
- 제7항에 있어서, 포화된 아실사슬 지질은 디팔미토일 포스파티딜콜린인 것을 특징으로 하는 방법.
- 제1항에 있어서, 완충액은 시트르산 완충액인 것을 특징으로 하는 방법.
- 제9항에 있어서, 시트르산 완충액의 pH4.5인 것을 특징으로 하는 방법.
- 제1항에 있어서, 동물은 세포활성, 흡착, 염증, 독혈증의 질환을 가지고 대사물질의 항-질환 효과량을 동물에 투여하는 것으로 구성된 것을 특징으로 하는 방법.
- 제11항에 있어서, 질환은 재환류손상, 조직적 염증반응증후군, 심근경색, 성인 호흡곤란 증후군, 맥관염, 화상, 외상후 쇼크, 맥관-차단질환 또는 관절염과 자가면역질환으로 구성된 것을 특징으로 하는 방법.
- 제12항에 있어서, 관절염은 류마티스 관절염, 통풍 또는 필라리 관절염인 것을 특징으로 하는 방법.
- 제12항에 있어서, 자가면역질환은 조직적 홍반성 낭창, 청소년 당뇨명, 다발성 경화증 또는 하시모토 갑상선염인 것을 특징으로 하는 방법.
- 제12항에있어서, 질환은 조직적 염증반응 증후군인 것을 특징으로 하는 방법.
- 제12항에 있어서, 질환은 성인호흡 곤란증후군인 것을 특징으로 하는 방법.
- 제11항에 있어서, 대사물질의 효과량은 동물체중 kg당 대사물질 약 10-12g이상인 것을 것을 특징으로 하는 방법.
- 제17항에 있어서, 대사물질의 효과량은 동물체중 kg당 대사물질 약 10-12g 내지 10-3g이상인 것을 것을 특징으로 하는 방법.
- 제18항에 있어서, 대사물질의 효과량은 동물체중 kg당 대사물질 약 10-8g 내지 10-4g이상인 것을 것을 특징으로 하는 방법.
- 제19항에 있어서, 대사물질의 효과량은 동물체중 kg당 대사물질 약 10-6g이상인 것을 것을 특징으로 하는 방법.
- 제1항에 있어서, 리포좀은 건조 보호제로 구성된 것을 특징으로 하는 방법.
- 제21항에 있어서, 건조보호제는 사카라이드인 것을 특징으로 하는 방법.
- 제22항에 있어서, 사카라이드는 말토즈, 락토즈, 덱스트로즈, 트레할로즈, 라피노즈 또는 슈크로즈인 것을 특징으로 하는 방법.
- 제23항에 있어서, 사카라이드 말토즈인 것을 특징으로 하는 방법.
- 제1항에 있어서, 동물에 추가의 생활성제를 투여하는 것으로 구성된 것을 특징으로 하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14789893A | 1993-11-04 | 1993-11-04 | |
US08/147898 | 1993-11-04 | ||
US08/147,898 | 1993-11-04 | ||
US15285293A | 1993-11-16 | 1993-11-16 | |
US08/152852 | 1993-11-16 | ||
US08/152,852 | 1993-11-16 | ||
US18008994A | 1994-01-11 | 1994-01-11 | |
US08/180089 | 1994-01-11 | ||
US08/180,089 | 1994-01-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR960705544A true KR960705544A (ko) | 1996-11-08 |
KR100355246B1 KR100355246B1 (ko) | 2003-01-06 |
Family
ID=27386612
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960702299A KR100355246B1 (ko) | 1993-11-04 | 1994-11-03 | 단층라멜라리포좀성아라키돈산대사물질조성물을사용한치료방법 |
KR1019960702298A KR100355247B1 (ko) | 1993-11-04 | 1994-11-03 | 다층라멜라리포좀성아라키돈산대사물질 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960702298A KR100355247B1 (ko) | 1993-11-04 | 1994-11-03 | 다층라멜라리포좀성아라키돈산대사물질 |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP0726763B1 (ko) |
JP (2) | JPH09504793A (ko) |
KR (2) | KR100355246B1 (ko) |
AT (2) | ATE191141T1 (ko) |
AU (2) | AU8130894A (ko) |
CA (2) | CA2175896A1 (ko) |
DE (2) | DE69420859T2 (ko) |
DK (2) | DK0726764T3 (ko) |
ES (2) | ES2144118T3 (ko) |
GR (2) | GR3032006T3 (ko) |
NO (2) | NO312809B1 (ko) |
PT (1) | PT726763E (ko) |
WO (2) | WO1995012389A1 (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0939628B1 (en) * | 1996-07-22 | 2003-03-05 | Monsanto Company | Thiol sulfone metalloprotease inhibitors |
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
WO1998039316A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
US6638952B1 (en) | 1997-03-04 | 2003-10-28 | Pharmacia Corporation | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
US20010039287A1 (en) | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
NZ503485A (en) | 1997-11-14 | 2002-10-25 | G | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6448250B1 (en) | 1999-02-08 | 2002-09-10 | G. D. Searle & Company | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6583299B1 (en) | 1999-05-20 | 2003-06-24 | G.D. Searle & Co. | α-amino-β-sulfonyl hydroxamic acid compounds |
US6683078B2 (en) | 2001-07-19 | 2004-01-27 | Pharmacia Corporation | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
JP2003342196A (ja) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | 静脈注射用組成物、その製造法およびその製剤 |
WO2013039851A1 (en) | 2011-09-12 | 2013-03-21 | Mallinckrodt Llc | Optical agents for imaging and visualization of matrix metalloproteinase enzymes |
CN111053743B (zh) * | 2018-10-16 | 2023-07-14 | 石药集团中奇制药技术(石家庄)有限公司 | 一种前列地尔脂质体及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU617678B2 (en) * | 1987-05-22 | 1991-12-05 | Liposome Company, Inc., The | Prostaglandin-lipid formulations |
US5262168A (en) * | 1987-05-22 | 1993-11-16 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
JPH0395118A (ja) * | 1989-09-07 | 1991-04-19 | Green Cross Corp:The | プロスタグランジン含有脂肪小体製剤 |
JPH04356421A (ja) * | 1991-03-06 | 1992-12-10 | Green Cross Corp:The | プロスタグランジン類含有脂肪小体組成物 |
DK0512916T3 (da) * | 1991-05-07 | 1999-09-20 | Liposome Co Inc | Liposomale prostaglandinformuleringer |
JPH05139977A (ja) * | 1991-05-17 | 1993-06-08 | Green Cross Corp:The | プロスタグランジン類リポソーム複合体を充填した注射器 |
-
1994
- 1994-11-03 AT AT95900504T patent/ATE191141T1/de not_active IP Right Cessation
- 1994-11-03 JP JP7513436A patent/JPH09504793A/ja not_active Abandoned
- 1994-11-03 EP EP95900504A patent/EP0726763B1/en not_active Expired - Lifetime
- 1994-11-03 DE DE69420859T patent/DE69420859T2/de not_active Expired - Fee Related
- 1994-11-03 ES ES95900504T patent/ES2144118T3/es not_active Expired - Lifetime
- 1994-11-03 AT AT95900532T patent/ATE184785T1/de not_active IP Right Cessation
- 1994-11-03 WO PCT/US1994/012710 patent/WO1995012389A1/en active IP Right Grant
- 1994-11-03 KR KR1019960702299A patent/KR100355246B1/ko not_active IP Right Cessation
- 1994-11-03 ES ES95900532T patent/ES2136271T3/es not_active Expired - Lifetime
- 1994-11-03 DK DK95900532T patent/DK0726764T3/da active
- 1994-11-03 DK DK95900504T patent/DK0726763T3/da active
- 1994-11-03 WO PCT/US1994/012579 patent/WO1995012388A1/en active IP Right Grant
- 1994-11-03 JP JP7513378A patent/JPH09511216A/ja active Pending
- 1994-11-03 AU AU81308/94A patent/AU8130894A/en not_active Abandoned
- 1994-11-03 CA CA002175896A patent/CA2175896A1/en not_active Abandoned
- 1994-11-03 EP EP95900532A patent/EP0726764B1/en not_active Expired - Lifetime
- 1994-11-03 AU AU81326/94A patent/AU687921B2/en not_active Ceased
- 1994-11-03 DE DE69423773T patent/DE69423773T2/de not_active Expired - Fee Related
- 1994-11-03 CA CA002175057A patent/CA2175057A1/en not_active Abandoned
- 1994-11-03 KR KR1019960702298A patent/KR100355247B1/ko not_active IP Right Cessation
- 1994-11-03 PT PT95900504T patent/PT726763E/pt unknown
-
1996
- 1996-05-02 NO NO19961778A patent/NO312809B1/no not_active IP Right Cessation
- 1996-05-02 NO NO19961779A patent/NO312810B1/no not_active IP Right Cessation
-
1999
- 1999-11-30 GR GR990403099T patent/GR3032006T3/el unknown
-
2000
- 2000-06-29 GR GR20000401517T patent/GR3033817T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960705544A (ko) | 단층라멜라 리포좀성 아라키돈산 대사물질 조성물을 사용한 치료방법(methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations) | |
RU2238083C2 (ru) | Лечение хронической экземы кожи рук | |
CA2046943A1 (en) | Process for producing an agent with the active substance flupirtine to combat muscular tension | |
DE9320925U1 (de) | Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen | |
ES2204552T3 (es) | Metodo y composicion para tratar el acne. | |
KR920703041A (ko) | 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법 | |
TW197423B (ko) | ||
HALL | Beneficial effects of acute intravenous ibuprofen on neurologic recovery of head-injured mice: comparison of cyclooxygenase inhibition with inhibition of thromboxane A2 synthetase or 5-lipoxygenase | |
Reiz et al. | EMLA--a eutectic mixture of local anaesthetics for topical anaesthesia | |
IT1255968B (it) | Composizioni farmaceutiche contenenti acido ursodesossicolico | |
Gutsell | Sulfa drugs and the treatment of furunculosis in trout | |
KR960705546A (ko) | 아라키돈산 대사물질을 포함하는 인터디지테이션-퓨젼 리포좀(interdigitation-fusion liposomes containing arachidonic acid metabolites) | |
Arankowsky-Sandoval et al. | Enhancement of REM sleep with auditory stimulation in young and old rats | |
RU1782598C (ru) | "Антиколибактериозный состав дл новорожденных тел т - "Симофин-2" | |
JPH07277983A (ja) | プロスタグランジンe1関連化合物含有坐剤およびその医薬用途 | |
JPH07277984A (ja) | プロスタグランジンe1関連化合物含有坐剤およびその医薬用途 | |
Iinuma et al. | Childhood epilepsy uncontrolled by phenytoin: clinical and electroencephalographic study | |
JPH0121130B2 (ko) | ||
Vladimirsky et al. | Efficacy of streptomycin incorporated into liposomes in treatment of mice with experimental tuberculosis. | |
王小马 | ELECTROIMPULSE ACUPUNCTURE TREATMENT OF 110 CASES OF ABDOMINAL PAIN AS A SEOUELA OF ABDOMINAL SURGERY | |
RU92013616A (ru) | Способ лечения эрозии шейки матки | |
JPH0388511U (ko) | ||
RU93026052A (ru) | Мазь для лечения заболеваний с нарушением коротинизации и целостности кожи | |
RU92015142A (ru) | Состав противомикробных суспензий | |
RU95110493A (ru) | Средство для лечения кожных заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20060307 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |